We’re in one of those markets where it seems like nothing is working. The pain starts early with the evening S & P and Nasdaq futures giving you a double dose of crimson. But the trusty S & P Short Range Oscillator isn’t oversold enough to hold your nose and buy something. So you just…
Psilocybin mushrooms stand ready for harvest in a humidified “fruiting chamber.” John Moore | Getty Images Thursday’s announcement that Eli Lilly will acquire AtaiBeckley, a clinical-stage maker of psychedelic drugs, for up to $3.8 billion indicates Big Pharma’s increasing embrace of a long-stigmatized class of medications as alternatives for treating an array of mental health…
A beautiful, but over weight Maine Coon Cat gets measured around the belly by a vet. Ryersonclark | E+ | Getty Images Felix is five years old, loves food, and refuses to lose weight. His owner, Amy in Dallas, has tried cutting back on meals, but with two cats in the house, “he just gobbles…
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. As new GLP-1 drugs enter the U.S. market and landmark Medicare coverage rolls out, one thing remains the same: Most employers still aren’t covering those drugs for…
Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage of obesity drugs. Starting Wednesday, eligible beneficiaries can get GLP-1s to treat obesity for a copay of just $50 per month. It’s a watershed move that could unlock a vast new patient population for Novo Nordisk and…
Eli Lilly and Regeneron are among the first seven companies the U.S. Food and Drug Administration selected for a pilot program designed to accelerate reviews of new domestic pharmaceutical manufacturing facilities, CNBC has learned. Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in the FDA’s…
I sure didn’t want what happened to occur, at least not during my vacation, of all things. But it did, and we have to deal with the fallout head-on because it came as such a surprise to many. Imagine for a moment there were five geese — Amazon , Alphabet , Microsoft , Meta Platforms ,…
Whitebalance.space | E+ | Getty Images America’s “protein-maxxing” obsession is stressing the dairy industry. Whey protein concentrate, once considered a cheap byproduct of the cheese manufacturing process, has become one of the most in-demand ingredients in the American diet. The surge is creating nationwide shortages, with some suppliers sold out for the latter half of…
Injection pens for the weight loss treatment Wegovy, manufactured by Novo Nordisk A/S, on display during a news conference in Mumbai, India, June 24, 2025. Dhiraj Singh | Bloomberg | Getty Images Millions of older Americans in Medicare are about to gain access to obesity drugs for the first time — but that landmark shift…
Wall Street spent the week debating who the biggest winners and losers of the artificial intelligence boom will ultimately be. Memory chipmaker Micron’s blockbuster earnings reinforced the fervent demand for computing resources, but it also led investors to question whether the AI buildout is becoming too expensive for the hyperscalers funding it. The tech-heavy Nasdaq…
